Pharma BD Deal Intelligence
CoolSculpting fit Allergan's (then AbbVie's) aesthetics strategy but the ~$2.5B asset needed a ~$1.0B write-down within six years of the deal, undercut by early revenue erosion, a high-profile disfigurement lawsuit, and a self-inflicted marketing misstep — a franchise that never earned its purchase price back.
Full analysis, sources & comparables →BioPharma Dive noted the deal would be 'immediately accretive,' citing Zeltiq's $354M FY2016 sales and 17-20% projected 2017 growth. Cited MarketsAndMarkets…
Fortune highlighted the 14.4% premium to prior close and contextualized the deal as part of CEO Brent Saunders's acquisitive playbook following the failed…
BioWorld characterized the deal as portfolio reshaping that adds the FDA-cleared CoolSculpting franchise as the third pillar of Allergan's medical aesthetics…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Allergan agreed to acquire Zeltiq Aesthetics for $56.50/share in cash, total enterprise value approximately $2.47B. The deal added the FDA-cleared CoolSculpting System to Allergan's medical aesthetics platform as a third pillar alongside facial aesthetics and breast/regenerative medicine. Closed April 28, 2017.
CoolSculpting fit Allergan's (then AbbVie's) aesthetics strategy but the ~$2.5B asset needed a ~$1.0B write-down within six years of the deal, undercut by early revenue erosion, a high-profile disfigurement lawsuit, and a self-inflicted marketing misstep — a franchise that never earned its purchase price back.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Allergan plc / Zeltiq Aesthetics, Inc. (this deal) | 2017 | $2.5B | 32 |
| Allergan plc / Merck & Co., Inc. (CGRP receptor antagonist program) | 2015 | $250M | 91 |
| Allergan plc / SkinMedica, Inc. | 2012 | $375M | 55 |
| Allergan plc / Inamed Corporation | 2005 | $3.2B | 50 |
| Allergan plc / Oculeve, Inc. | 2015 | $250M | 33 |
| Allergan plc / Kythera Biopharmaceuticals, Inc. | 2015 | $2.1B | 23 |
| Allergan plc / Anterios, Inc. | 2016 | $90M | 19 |
← Browse all deals · How we score deals
More: 2017 deals · Allergan plc deals · Other deals